Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy

To determine the potential value of multimodal MRI for the presurgical management of patients with brain tumors, we performed combined magnetic resonance imaging (MRI) and proton MR spectroscopy (MRS) in 164 patients who presented with tumors of various histological subtypes confirmed by surgical biopsy. Univariate statistical analysis of metabolic ratios carried out on the first 121 patients demonstrated significant differences in between‐group comparisons, but failed to provide sufficiently robust classification of individual cases. However, a multivariate statistical approach correctly classified the tumors using linear discriminant analysis (LDA) of combined MRI and MRS data. After initial separation of contrast‐enhancing and non‐contrast‐enhancing lesions, 91% of the former and 87% of the latter were correctly classified. The results were stable when this diagnostic strategy was tested on the additional 43 patients included for validation after the initial statistical analysis, with over 90% of correct classification. Combined MRI and MRS had superior diagnostic value compared to MRS alone, especially in the contrast‐enhancing group. This study shows the clinical value of a multivariate statistical analysis based on multimodal MRI and MRS for the noninvasive evaluation of intracranial tumors. Magn Reson Med, 2006. © 2006 Wiley‐Liss, Inc.

[1]  Thomas Dierks,et al.  Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. , 2003, Journal of neurosurgery.

[2]  Combined MR measurements of magnetization transfer, tissue diffusion and proton spectroscopy. A feasibility study with neurological cases , 2003, Neurological research.

[3]  Sylvie Grand,et al.  A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images , 2000, Nature Medicine.

[4]  H. Lanfermann,et al.  Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions , 2002, Neuroradiology.

[5]  D K Pearl,et al.  Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.

[6]  Christophe Ladroue,et al.  Independent component analysis for automated decomposition of in vivo magnetic resonance spectra , 2003, Magnetic resonance in medicine.

[7]  J. Vion-Dury,et al.  A multiparametric data analysis showing the potential of localized proton MR spectroscopy of the brain in the metabolic characterization of neurological diseases , 1993, Journal of Neurological Sciences.

[8]  D. Hoffmann,et al.  Necrotic tumor versus brain abscess: importance of amino acids detected at 1H MR spectroscopy--initial results. , 1999, Radiology.

[9]  Blake A. Johnson,et al.  The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. , 1997, AJNR. American journal of neuroradiology.

[10]  D. Galanaud,et al.  Regional metabolite levels of the normal posterior fossa studied by proton chemical shift imaging , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.

[11]  Risto A. Kauppinen,et al.  Diagnostic assessment of brain tumours and non-neoplastic brain disorders in vivo using proton nuclear magnetic resonance spectroscopy and artificial neural networks , 1999, Journal of Cancer Research and Clinical Oncology.

[12]  L. Astrakas,et al.  Noninvasive Magnetic Resonance Spectroscopic Imaging Biomarkers to Predict the Clinical Grade of Pediatric Brain Tumors , 2004, Clinical Cancer Research.

[13]  Arend Heerschap,et al.  Combination of feature‐reduced MR spectroscopic and MR imaging data for improved brain tumor classification , 2005, NMR in biomedicine.

[14]  D. Galanaud,et al.  Multimodal magnetic resonance imaging of the central nervous system. , 2003, Biochimie.

[15]  P. Lai,et al.  Brain abscess and necrotic brain tumor: discrimination with proton MR spectroscopy and diffusion-weighted imaging. , 2002, AJNR. American journal of neuroradiology.

[16]  A. W. Simonetti,et al.  The use of multivariate MR imaging intensities versus metabolic data from MR spectroscopic imaging for brain tumour classification. , 2005, Journal of magnetic resonance.

[17]  V. L. Doyle,et al.  Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy , 2003, Magnetic resonance in medicine.

[18]  R. Henry,et al.  Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. , 2000, AJNR. American journal of neuroradiology.

[19]  H. Bruhn,et al.  Localized high‐resolution proton NMR spectroscopy using stimulated echoes: Initial applications to human brain in vivo , 1989, Magnetic resonance in medicine.

[20]  W. Schlote,et al.  Preoperative Proton-MR Spectroscopy of Gliomas – Correlation with Quantitative Nuclear Morphology in Surgical Specimen , 2003, Journal of Neuro-Oncology.

[21]  KLAUS-DIETMARMERFSOLDT Jensfrahm.  Localized Proton Spectroscopy Using Stimulated Echoes , 2004 .

[22]  Damien Galanaud,et al.  Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. , 2003, Journal of neurosurgery.

[23]  C Morriss,et al.  Prediction of posterior fossa tumor type in children by means of magnetic resonance image properties, spectroscopy, and neural networks. , 1997, Journal of neurosurgery.

[24]  M. Chamberlain.  Gliomatosis cerebri , 2004, Neurology.

[25]  Christopher Nimsky,et al.  Integration of biochemical images of a tumor into frameless stereotaxy achieved using a magnetic resonance imaging/magnetic resonance spectroscopy hybrid data set. , 2004, Journal of neurosurgery.

[26]  J. Frahm,et al.  On the identification of cerebral metabolites in localized 1H NMR spectra of human brain In vivo , 1991, NMR in biomedicine.

[27]  J. Vion-Dury,et al.  Brain proton magnetic resonance spectroscopy in HIV-related encephalopathy: identification of evolving metabolic patterns in relation to dementia and therapy. , 1997, AIDS research and human retroviruses.

[28]  E. Neuwelt,et al.  MR of primary CNS lymphoma in immunologically normal patients. , 1992, AJNR. American journal of neuroradiology.

[29]  Gerhard Schroth,et al.  Use of diffusion-weighted magnetic resonance imaging in differentiating purulent brain processes from cystic brain tumors. , 2002, Journal of neurosurgery.

[30]  T. Makabe,et al.  Assessment of the pathological grade of astrocytic gliomas using an MRI score , 1994, Neuroradiology.

[31]  P Abdolmaleki,et al.  Neural networks analysis of astrocytic gliomas from MRI appearances. , 1997, Cancer letters.

[32]  W. Heindel,et al.  Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-L-alpha-methyltyrosine SPECT. , 2002, Radiology.

[33]  O. Chinot,et al.  Histological and MR Correlations in Gliomatosis cerebri , 2002, Journal of Neuro-Oncology.

[34]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[35]  Carles Arús,et al.  Proton magnetic resonance spectroscopy (1H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization , 2003, European Radiology.

[36]  K. Fountas,et al.  Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. , 2004, Neurosurgery.